UPDATE: Incyte (INCY) Tops Q3 EPS by 12c, Beats on Revenues; Boosts FY17 Jakafi Net Product Revenue Guidance
Incyte (NASDAQ: INCY) reported Q3 EPS of $0.17, $0.12 better than the analyst estimate of $0.05. Revenue for the quarter came in at $381.53 million versus the consensus estimate of $359.7 million.
- $304 million of 2017 third-quarter net product revenues from Jakafi® (ruxolitinib), representing 36 percent growth over the same period last year
- Progress across the portfolio as multiple candidates enter late-stage development trials
- Two recent collaborations further expand potential and scope of Incyte’s combination immunotherapy development activities
For earnings history and earnings-related data on Incyte (INCY) click here.